Skip to main content
REVELATION BIOSCIENCES, INC. logo

REVELATION BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · REVB ISIN · US7164211028 LEI · 549300UKS15BEXENY615 US Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2026-06-01 Report Publication Anno…
Country US United States of America
Listing US REVB

About REVELATION BIOSCIENCES, INC.

https://www.revbiosciences.com/

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic-based therapies for the prevention and treatment of disease. The company's core strategy involves rebalancing inflammation and harnessing the innate immune system to optimize health. Its lead product candidate, Gemini, is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®). Gemini is designed to reprogram the innate immune system to respond to stressors like trauma and infection in an attenuated manner, thereby reducing inflammation-associated damage. The company is evaluating Gemini for various applications, including the prevention of post-surgical infections and acute kidney injury.

Recent filings

Filing Released Lang Actions
8-K
Report Publication Announcement Classification · 92% confidence The document is a Current Report on Form 8-K announcing that an updated corporate presentation has been released and is attached as Exhibit 99.1. It does not contain substantive financial data or other report content itself but simply states that the presentation is available on the company’s website and attached. Under the “menu vs meal” rule, this is a publication announcement of a corporate presentation, matching the Report Publication Announcement category (RPA).
2026-06-01 English
DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Proxy Solicitation & Information Statement
2026-05-11 English
ARS - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Annual Report
2026-05-11 English
S-8 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 filing, which is a registration statement used by companies to register securities to be offered to employees under employee benefit plans. The content includes a calculation of filing fees related to newly registered securities under an inducement plan and employee awards. This type of filing is related to share issuance and capital changes rather than financial results, management changes, or other report types. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is short and specific to registration fees, not an announcement of a report or a certification, so it is not RPA or RNS.
2026-04-15 English
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes. The content focuses on a Special Meeting of Stockholders held on March 18, 2026, where stockholders approved issuance of shares exceeding the Nasdaq Exchange Cap and discretionary authority to adjourn the meeting. It includes voting results and details about the stock issuance rights. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a proxy solicitation or a remuneration report. It is a regulatory announcement of a corporate event and voting results. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2026-03-19 English
8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing financial results for the quarter and year ended December 31, 2025. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3707 characters, which is relatively short and consistent with a current report announcing earnings results rather than the earnings release itself. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). However, since this is a Form 8-K filing that includes a press release announcing financial results, and the press release is furnished as an exhibit, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory current report referencing an earnings announcement rather than the earnings release document itself. The document does not contain the full earnings release text or detailed financial data, only a reference to it.
2026-02-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.